• Temozolomide: Small-Molecule Alkylating Agent in Glioma Rese

  2026-06-30

  Temozolomide is a validated small-molecule alkylating agent that induces DNA damage and is pivotal in glioma research. Its defined mechanism, bench-tested cytotoxicity, and robust solubility profile make it essential for DNA repair and chemotherapy resistance studies.

• Trolox in Organoid and Oxidative Injury Research: Applied Wo

  2026-06-30

  Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) is redefining antioxidant benchmarking and functional assay optimization, from high-throughput organoid models to translational cancer biology. Discover how APExBIO’s cell-permeable Trolox supports advanced workflows and robust troubleshooting in oxidative injury research.

• G-Quadruplex Modulation of TDP-43 Aggregation in Neurodegene

  2026-06-29

  Oldani et al. (2025) demonstrate that RNA G-quadruplexes directly modulate TDP-43 protein condensation and toxicity in both in vitro and cellular models. This work uncovers a novel structural mechanism contributing to neurodegenerative proteinopathies and highlights the therapeutic potential of targeting G-quadruplex structures.

• Dissecting Drug Responses in Cancer: In Vitro Evaluation Adv

  2026-06-29

  Schwartz’s dissertation introduces a refined framework for distinguishing between cancer cell proliferation inhibition and cell death in in vitro drug testing. By separating relative and fractional viability measurements, the study clarifies how agents like HDAC inhibitors modulate tumor cell fate, guiding improved experimental design and analysis for oncology research.

• Vemurafenib (PLX4032): Systems-Level Resistance and Research

  2026-06-28

  Explore the systems biology of Vemurafenib (PLX4032) in melanoma research, with a unique focus on integrative resistance mechanisms and advanced assay optimization. Discover how multi-omics insights reshape experimental design for metastatic melanoma studies.

• Trolox in Redox Signaling: Mechanistic Insights for Oxidativ

  2026-06-27

  Explore the mechanistic role of Trolox in redox-sensitive pathways and its unique applications in oxidative injury research. This article delivers advanced analysis of 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, setting a new benchmark for scientific rigor in antioxidant assay design.

• H 89 2HCl (SKU B2190): Precision PKA Inhibition in Cell Assa

  2026-06-26

  This article provides an evidence-based, scenario-driven exploration of H 89 2HCl (SKU B2190) for dissecting cAMP/PKA signaling in cellular assays. Researchers will find practical guidance for optimizing assay sensitivity, controlling kinase selectivity, and ensuring data reproducibility. APExBIO’s H 89 2HCl is examined in the context of real lab challenges and advanced protocol considerations.

• 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole: Beyond Elonga

  2026-06-26

  Explore the multifaceted roles of 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) as a transcriptional elongation inhibitor, with fresh insight into its modulation of cyclin-dependent kinase pathways and stem cell fate. This article delivers a systems biology view and practical assay implications not found in previous reviews.

• ECM Remodeling Drives Mitochondrial Fission via TGF-β Signal

  2026-06-25

  Zhang et al. (2024) uncover an evolutionarily conserved pathway where extracellular matrix (ECM) remodeling, specifically hyaluronan degradation, initiates mitochondrial fission and stress responses through TGF-β signaling. This ECM-mitochondria crosstalk enhances immune defense mechanisms and provides new avenues for mitochondrial dynamics research.

• Z-DEVD-FMK (SKU A1920): Reliable Caspase-3 Inhibitor Solutio

  2026-06-25

  This evidence-driven article addresses key workflow challenges in apoptosis and neuroprotection research, demonstrating how Z-DEVD-FMK (SKU A1920) delivers reproducible, mechanistically validated results. Practical Q&A scenarios guide researchers through protocol optimization, data interpretation, and reliable product selection, with a focus on leveraging the dual caspase/calpain inhibition of Z-DEVD-FMK for robust experimental outcomes.

• ATM Inhibition and Fenofibrate Synergy in Ovarian Cancer Mod

  2026-06-24

  This study identifies ATM kinase as a therapeutic vulnerability in high grade serous ovarian cancer (HGSOC) with homologous recombination proficiency. Combined ATM inhibition and fenofibrate treatment synergistically induce senescence in HGSOC cells, suggesting a metabolic strategy for overcoming therapy resistance.

• Leupeptin Hemisulfate Salt: Precision for Protease Activity

  2026-06-23

  Leupeptin hemisulfate salt sets the benchmark for reversible, nanomolar inhibition of serine and cysteine proteases—empowering reliable protein degradation, viral replication, and autophagy studies. This guide demystifies experimental workflows, troubleshooting strategies, and cross-domain applications, drawing on the latest advances in metabolic-epigenetic research.

• Asunaprevir (BMS-650032): Advanced HCV NS3 Protease Inhibiti

  2026-06-23

  Asunaprevir (BMS-650032) delivers potent, broad-spectrum HCV NS3 protease inhibition that streamlines hepatitis C research across diverse genotypes and cell models. This article details practical workflow enhancements, protocol parameters, and troubleshooting strategies to maximize experimental success with this APExBIO offering.

• Technical Use of Hoechst 33342/PI Double Staining Kit (K2237

  2026-06-22

  The Hoechst 33342/PI Double Staining Kit addresses the need for rapid, fluorescence-based differentiation of apoptotic, necrotic, and viable cells in research settings. It is suitable for microscopy or flow cytometry workflows but should not be used for diagnostic or clinical applications.

• SCUBE3 Antibody Targeting Suppresses Tumor Growth and Immuno

  2026-06-22

  This study identifies secretory protein SCUBE3 as a central driver of tumor progression and therapy resistance through oncogenic signaling and immune evasion. Antibody-mediated neutralization of SCUBE3 disrupts these processes, resulting in substantial tumor suppression and restored antitumor immunity, with implications for pan-cancer therapeutic strategies.

422 records 11/29 page Previous Next First page 上5页 1112131415 下5页 Last page